Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296837 · ClinicalTrials.gov registry record · Phase 4
Ocular Rosacea Biome Study
A Phase 4 study of Antimicrobial Resistance and Ocular Rosacea, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05296837 is a Phase 4 study of Antimicrobial Resistance and Ocular Rosacea that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05296837, a Phase 4 study of Antimicrobial Resistance and Ocular Rosacea, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe. Ocular rosacea may cause chronic eye redness, blepharitis, recurrent chalazia, dry eye, corneal erosion, corneal vascularization, and corneal ulceration. Rosacea affecting the cornea can result in vision loss. Prescription eye drops and ointments can be used topically to control mild ocular rosacea. However, severe disease, or rosacea that is not well controlled with local treatments is treated systemically. The most commonly used systemic treatment for rosacea is the bacteriostatic antibiotic doxycycline. Rosacea treatment doses of doxycycline vary widely. Treatment-dose doxycycline for systemic infections is 100mg twice a day. However, as rosacea is considered an inflammatory disease, doxycycline is often dosed at what is termed, sub-microbial dose doxycycline (SDD). Initially introduced in the oral medicine literature, SDD are doses 40mg and lower because systemic administration at this dose does not appear to alter the oral mucosa flora or increase resistance rates when given long-term for periodontal disease. Whereas 100mg doxycycline, even when given short term, may increase the percentage of culturable nasopharyngeal flora that is resistant to doxycycline. The FDA does not categorize SDD an antibiotic, stating this dosing is expected to exhibit only anti-inflammatory activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline 40 MG ( 20mg twice daily)
- DRUG Doxycycline 200 MG ( 100 mg twice daily)
Study Locations (1)
California
- University of California, San Farncisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296837
The ClinicalTrials.gov registry entry for NCT05296837 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Antimicrobial Resistance appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05296837 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05296837 about?
NCT05296837 is a clinical study titled "Ocular Rosacea Biome Study". Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe. Ocular rosacea may cause chronic eye redness, blepharitis, recurrent chalazia, dry eye, corneal er...
What is the current status of trial NCT05296837?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-06-22. Estimated completion is 2026-07-31.
What conditions does trial NCT05296837 study?
This clinical trial studies the following conditions: Antimicrobial Resistance, Ocular Rosacea.
What interventions are being tested in trial NCT05296837?
The interventions under investigation include: Placebo (DRUG), Doxycycline 40 MG ( 20mg twice daily) (DRUG), Doxycycline 200 MG ( 100 mg twice daily) (DRUG).
Who is sponsoring clinical trial NCT05296837?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296837 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antimicrobial Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.